Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 1/20 | 0.46 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.39 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17590498 | 1.00 | METAP1 (0.46) | METAP1GABRR1CYP1A2METAP2HPGD | |
| SCHEMBL6987701 | 1.00 | METAP1 (0.46) | METAP1GABRR1CYP1A2METAP2HPGD | |
| SCHEMBL27488750 | 0.91 | ACE2 (0.44) | METAP1GABRR1CYP1A2METAP2HPGD | |
| SCHEMBL6156004 | 0.89 | CYP1A2 (0.45) | METAP1GABRR1CYP1A2SIGMAR1BLM | |
| SCHEMBL27486952 | 0.89 | ACE2 (0.46) | METAP1GABRR1CYP1A2METAP2SLC1A3 | |
| SCHEMBL18050478 | 0.89 | CYP1A2 (0.45) | METAP1GABRR1CYP1A2SIGMAR1BLM | |
| SCHEMBL27601862 | 0.85 | METAP1 (0.41) | METAP1METAP2HPGDSLC1A3SLC1A2 | |
| SCHEMBL28740646 | 0.85 | ACE2 (0.46) | METAP1GABRR1CYP1A2SLC1A3SLC1A2 | |
| SCHEMBL27602009 | 0.83 | METAP1 (0.39) | METAP1GABRR1CYP1A2METAP2BLM | |
| SCHEMBL931400 | 0.82 | METAP1 (0.49) | METAP1CYP1A2METAP2HPGDSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9446021-B2 | Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof | DOGWOOD PHARMACEUTICALS, INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-9345789-B2 | Specific inhibitors and active site probes for legumain | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2016-05-24 | — | — | US | disclosed |
| US-20150313873-A1 | Derivatives of Fluorene, Anthracene, Xanthene, Dibenzosuberone and Acridine and Uses Thereof | DOGWOOD PHARMACEUTICALS, INC. | 2015-11-05 | — | — | US | disclosed |
| US-9120754-B2 | Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof | DOGWOOD PHARMACEUTICALS, INC. (US) | 2015-09-01 | — | — | US | disclosed |
| US-20120251459-A1 | SPECIFIC INHIBITORS AND ACTIVE SITE PROBES FOR LEGUMAIN | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2012-10-04 | — | — | US | disclosed |
| US-20120129837-A1 | Derivatives of Fluorene, Anthracene, Xanthene, Dibenzosuberone and Acridine and Uses Thereof | ALLERGAN SALES, LLC | 2012-05-24 | — | — | US | disclosed |
| US-8129519-B2 | Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof | ALLERGAN SALES, LLC | 2012-03-06 | — | — | US | disclosed |
| US-20100137354-A1 | DERIVATIVES OF FLUORENE, ANTHRACENE, XANTHENE, DIBENZOSUBERONE AND ACRIDINE AND USES THEREOF | ALLERGAN SALES, LLC | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129837-A1 | Derivatives of Fluorene, Anthracene, Xanthene, Dibenzosuberone and Acridine and Uses Thereof | WNT1, CTNND1, CTNNB1 | METAP1 4431/4885GABRR1 4697/4885CYP1A2 1764/4885 |
| US-20150313873-A1 | Derivatives of Fluorene, Anthracene, Xanthene, Dibenzosuberone and Acridine and Uses Thereof | WNT1, CTNND1, CTNNB1 | METAP1 4431/4885GABRR1 4697/4885CYP1A2 1764/4885 |
| US-20100137354-A1 | DERIVATIVES OF FLUORENE, ANTHRACENE, XANTHENE, DIBENZOSUBERONE AND ACRIDINE AND USES THEREOF | WNT1, CTNND1, CTNNB1 | METAP1 4431/4885GABRR1 4697/4885CYP1A2 1764/4885 |
| US-20120251459-A1 | SPECIFIC INHIBITORS AND ACTIVE SITE PROBES FOR LEGUMAIN | ENGASE, LGMN, DNPEP | METAP1 47/4885GABRR1 4313/4885CYP1A2 4100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.